Mossakowski Medical Research Institute, Polish Academy of Sciences and the Committee of Neurobiology of the Polish Academy of Sciences have the honor to invite you to participate

in the 16th International Symposium Molecular basis of pathology and therapy in neurological disorders,

which will be held on October 17-18, 2024 at the organizer's headquarters in Warsaw, A. Pawińskiego 5.

The detailed scientific program and other information about the Symposium can be found soon at: ncs2024.imdik.pan.pl

The registration fee for students and PhD students is PLN 300, for other participants PLN 350.

The abstracts are planned to be published in the journal Folia Neuropathologica,
the deadline for their submission (after completing the form on the Conference website) is October 9th, 2024.

For organizational matters, please contact Ms. Krystyna Wąsik This email address is being protected from spambots. You need JavaScript enabled to view it.tel. 22 6086 510,

We cordially invite you to take an active part in this event.

Konf Salińska

 

Mossakowski Medical Research Institute has joined BioForum Association!

BioForum is an organization whose collaboration and networking platform – CEBioForum – enables biotechnology professionals to collaborate, share ideas and create partnerships that can lead to joint research projects, joint technology development and knowledge exchange.

BioForum represents the collective voice of its members when interacting with regulatory bodies, government agencies, and policymakers either at National level or European one as member of European organization - EuropaBio.

We look forward to working together to exchange information, promote innovation, research results and best practices among member companies.

More information about BioForum:

Bioforum

  Tomasz Kulesza, PhD from the Laboratory of Molecular and Cellular Nephrology
is the laureate of the Scientific Award of the Polish Academy of Sciences in Gdańsk
for young scientists for the best creative work published in 2023.
Publication's title: „Pit 1 transporter (SLC20A1) as a key factor in the NPP1-mediated inhibition of insulin signaling in human podocytes”.
Laureates presented their winning publications during the ceremonial announcement of results and awarding of diplomas,
which took place at the headquarters of the Polish Academy of Sciences in Gdańsk.
Congratulations!
nagroda dr Tomasz Kulesza zdj

Dorota Rogacka, PhD is laureate of the Professor Tadeusz Browicz Award,
which is granted for outstanding achievements in the field of medicine by the Polish Academy of Arts and Sciences
at the request of the 5th Faculty of Medicine of the Polish Academy of Arts and Sciences for a series of publications entitled:
"Nitric oxide and cyclic GMP-dependent mechanism for regulating the sensitivity of podocyte cells to insulin:
influence on podocyte functions in hyperglycemia"

Dorota Rogacka www ENG

 

 

 

The manuscript entitled “Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models” was recently published in the Haematologica journal (IF=10.1).
It is the result of cooperation between the team of Małgorzata Firczuk, PhD from the Department of Immunology MMRI PAS and research groups from the Medical University of Lodz, the Institute of Hematology and Transfusion Medicine in Warsaw, and the Medical University of Silesia. The first author of the paper is a PhD student of MMRI PAS, Krzysztof Domka. Haematologica, founded in 1920, is one of the most prestigious journals in the field of hematology, publishing the results of clinical trials and preclinical studies of clinical importance.
The manuscript presents preclinical studies on the effectiveness of combination therapies in the treatment of acute lymphoblastic leukemia with the Philadelphia chromosome. The study assessed the efficacy of different combinations of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies directed against the CD20 protein. TKIs were observed to reduce the amount of CD20 on leukemic cells, which may reduce the efficacy of anti-CD20 antibodies. In addition, individual TKIs were shown to have different effects on immune cells, such as NK cells and macrophages, which are responsible for the efficacy of monoclonal antibodies. The next-generation TKI, asciminib, has emerged as the most promising drug, as it does not inhibit immune cell function, allowing optimal anti-leukemic activity of anti-CD20 antibodies. These findings may be crucial for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting the need for precise selection of TKIs for combination therapy with monoclonal antibodies. By proposing a new therapeutic combination, the study indicates potential opportunities to improve the efficacy of treatment for this aggressive form of leukemia.
https://doi.org/10.3324/haematol.2023.284853
 
Haematologica logo cut

 

  1. Symposium - invitation
  2. NCN funding for our researchers
  3. NCN grants for MMRI PAS researchers
  4. MMRI PAS at PACTT Conference